Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Autografting

Cyclophosphamide, etoposide and carboplatine plus non-cryopreserved autologous peripheral blood stem cell transplantation rescue for patients with refractory or relapsed non-Hodgkin's lymphomas

Bone Marrow Transplantation volume 37, pages 739–743 (2006)Cite this article

Abstract

A simplified schedule of high-dose chemotherapy consisting of cyclophosphamide (60 mg/kg/day for 2 days), etoposide (15 mg/kg/day for 2 days) and carboplatine (400 mg/m2/day for 2 days), together with autologous non-cryopreserved peripheral blood stem cells was used for treatment of relapsed (29 patients) and refractory (three patients) patients with non-Hodgkin's lymphoma (NHL). The use of such granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood stem cells (PBSC) after high-dose myeloablative therapy resulted in a rapid, complete and sustained hematopoietic recovery. The median time to achieve an absolute neutrophil count greater than 0.5 × 109/l was 12 days (range 8–17 days). The median time to self-sustained platelet count greater than 20 × 109/l was 14 days (range 7–19 days). Fifteen of the 32 patients (49%) were alive and disease free at a median follow-up of 18 months (range 10–96 months) for all surviving patients. The estimated 2-year overall survival (OS) and disease free survival (DFS) for all patients were 50 and 43%, respectively. Twelve patients died of relapse or progressive disease, two patients died of infection and one patient died of cardiac cause. The median time to relapse was 12 months (5–27) from PBSC infusion. High-dose chemotherapy with short-duration chemotherapy and non-cryopreserved bone marrow (BM) is an effective and safe treatment modality for patients with relapsed or resistant NHL.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Nademanee A, Molina A, O'Donnell MR, Dagis A, Snyder DS, Paker P et al. Results of high-dose therapy and autologous bone marrow/stem cell transplantation during remission in poor-risk intermediate- and high grade lymphoma: international index high and high intermediate risk group. Blood 1997; 90: 3844–3852.

    CAS  Google Scholar 

  2. Nademanee A, Molina A, Dagis A, Snyder DS, O'Donnell MR, Parker P et al. Autologous stem-cell transplantation for poor-risk and relapsed intermediate- and high-grade non-Hodgkin's lymphoma. Clin Lymphoma 2000; 1: 46–54.

    Article  CAS  Google Scholar 

  3. Martelli M, Gherlinzoni F, De Renzo A, Zinzani PL, De Vivo A, Cantonetti M et al. Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial. J Clin Oncol 2003; 7: 1255–1262.

    Article  Google Scholar 

  4. Hwang WL, Tsai CS, Jour JH, Kuo LH, Chang YM . Autologous peripheral blood stem cell transplantation using simplified procedures for collection and freezing. Zhonghua Yi Xue Za Zhi (Taipei) 1999; 62: 529–535.

    CAS  Google Scholar 

  5. Ahmed T, Wuest D, Ciavarella D, Ayello J, Feldman EJ, Biguzzi S et al. Marrow storage techniques: a clinical comparison of refrigeration versus cryopreservation. Acta Haematol 1991; 85: 173–178.

    Article  CAS  Google Scholar 

  6. Preti RA, Razis E, Ciavarella D, Fan Y, Kuhns RE, Cook P et al. Clinical and laboratory comparison study of refrigerated and cryopreserved bone marrow for transplantation. Bone Marrow Transplant 1994; 13: 253–260.

    CAS  PubMed  Google Scholar 

  7. Kaplan EL, Meier P . Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 157.

    Article  Google Scholar 

  8. Sierra J, Conde E, Iriondo A, Brunet S, Marin J, Perez de Oteiza J et al. Frozen vs nonfrozen bone marrow for autologous transplantation in lymphomas: a report from the Spanish GEL/TAMO Cooperative Group. Ann Hematol 1993; 67: 111–114.

    Article  CAS  Google Scholar 

  9. Lazarus HM, Pecora AL, Shea TC, Koc ON, White JM, Gabriel DA et al. CD34+ selection of hematopoietic blood cell collections and autotransplantation in lymphoma: overnight storage of cells at 4 degrees C does not affect outcome. Bone Marrow Transplant 2000; 25: 559–566.

    Article  CAS  Google Scholar 

  10. Ruiz-Arguelles GJ, Lobato-Mendizabal E, Ruiz-Arguelles A, Perez-Romano B, Arizpe-Bravo D, Marin-Lopez A . Non-cryopreserved unmanipulated hematopoietic peripheral blood stem cell autotransplant program: long-term results. Arch Med Res 1999; 30: 380–384.

    Article  CAS  Google Scholar 

  11. Ruiz-Arguelles GJ, Gomez-Rangel D, Ruiz-Delgado GJ, Ruiz-Arguelles A, Perez-Romano B, Rivadeneyra L . Results of an autologous noncryopreserved, unmanipulated peripheral blood hematopoietic stem cell transplant program: a single-institution, 10-year experience. Acta Haematol 2003; 110: 179–183.

    Article  Google Scholar 

  12. Nadmanee A, Sniecinki I, Schmidt GM, Dagis AC, Odonnell MR, Snyder DS et al. High dose therapy followed by autologous peripheral blood stem cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte stimulating factor-mobilized peripheral-blood stem cells. J Clin Oncol 1994; 12: 2176–2186.

    Article  Google Scholar 

  13. Schiffmann K, Bucckner CD, Maziarz R, Maloney DG, Appelbaum FR, Press O et al. High dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease. Biol Blood Marrow Transplant 1997; 3: 261–266.

    Google Scholar 

  14. Stockerl-Goldstein KE, Horning SJ, Negrin RS, Chao NJ, Hu WW, Long GD et al. Influence of preparatory regimen and source of hematopoietic cells on outcome of autotransplantation for non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 1996; 2: 76–85.

    CAS  Google Scholar 

  15. Stiff PJ, Dahlberg S, Forman SJ, McCall AR, Horning SJ, Nademanee AP et al. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens – a Southwest Oncology Group trial. J Clin Oncol 1998; 16: 48–55.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hematology and Medical Oncology Unit, Faculty of Medicine, Mansoura University, Mansoura, Egypt

    M Mabed & T Al-Kgodary

Authors
  1. M Mabed
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T Al-Kgodary
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M Mabed.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mabed, M., Al-Kgodary, T. Cyclophosphamide, etoposide and carboplatine plus non-cryopreserved autologous peripheral blood stem cell transplantation rescue for patients with refractory or relapsed non-Hodgkin's lymphomas. Bone Marrow Transplant 37, 739–743 (2006). https://doi.org/10.1038/sj.bmt.1705314

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705314

Keywords

This article is cited by

Search

Advanced search

Quick links